Uses
Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.
Source: US FDA prescribing information
Tretinoin is a retinoid indicated for topical application in the treatment of acne vulgaris. It is available as cream, gel and capsules for topical and oral use. MedsAcross supplies Tretinoin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.
Source: US FDA prescribing information
Tretinoin Cream should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment. Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. During the early weeks of therapy, an apparent exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy.
Source: US FDA prescribing information
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.
Source: US FDA prescribing information
General If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps, should be minimized during the use of tretinoin, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin. Tretinoin acne treatment should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes.
Source: US FDA prescribing information
The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin. To date, all adverse effects of tretinoin have been reversible upon discontinuance of therapy.
Source: US FDA prescribing information
Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin is begun.
Source: US FDA prescribing information
Conditions: Tretinoin Cream, 0.1%, 0.05%, and 0.025%: store below 80°F.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
24 presentations of Tretinoin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tretinoin 0.025% creamTopicalGeneric name | — | US FDA | Available on request |
| Tretinoin 0.1% creamTopicalGeneric name | — | US FDA | Available on request |
| Tretinoin 0.05% creamTopicalGeneric name | — | US FDA | Available on request |
| Tretinoin 0.01% gelTopicalGeneric name | — | US FDA | Available on request |
| Tretinoin 0.025% gelTopicalGeneric name | — | US FDA | Available on request |
| Tretinoin 10 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Tretinoin 0.08% gelTopicalGeneric name | — | US FDA | Available on request |
| Renova 0.02% creamTopical | Bausch Health | US FDA | Available on request |
| Tretinoin 0.05% gelTopicalGeneric name | — | US FDA | Available on request |
| Altreno 0.05% lotionTopical | Bausch Health | US FDA | Available on request |
| Tretinoin 0.04% gelTopicalGeneric name | — | US FDA | Available on request |
| Tretinoin 0.1% gelTopicalGeneric name | — | US FDA | Available on request |
| Retin-A 0.01% gelTopical | Bausch Health | US FDA | Available on request |
| Retin-A 0.025% creamTopical | Bausch Health | US FDA | Available on request |
| Retin-A 0.025% gelTopical | Bausch Health | US FDA | Available on request |
| Retin-A 0.05% creamTopical | Bausch Health | US FDA | Available on request |
| Retin-A 0.1% creamTopical | Bausch Health | US FDA | Available on request |
| Retin-A MICRO 0.08% gelTopical | Bausch Health | US FDA | Available on request |
| Atralin 0.05% gelTopical | Bausch Health | US FDA | Available on request |
| Retin-A MICRO 0.06% gelTopical | Bausch Health | US FDA | Available on request |
| Tretinoin 0.06% gelTopicalGeneric name | — | US FDA | Available on request |
| Tretinoin (Microsphere) 0.08% gelTopical | Mayne Pharma | US FDA | Available on request |
| Retin-A MICRO 0.04% gelTopical | Bausch Health | US FDA | Available on request |
| Retin-A MICRO 0.1% gelTopical | Bausch Health | US FDA | Available on request |
6 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 20 October 1971 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Tretinoin in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 24 presentations of Tretinoin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 6 brand names for Tretinoin, including Altreno, Atralin, Renova, Retin-A, Retin-A MICRO, Tretinoin (Microsphere).
Yes. The US FDA first approved Tretinoin on 20 October 1971, according to Drugs@FDA.
No listed presentation of Tretinoin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tretinoin is classified under ATC code D10AD01 (Tretinoin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.